169 related articles for article (PubMed ID: 29954928)
1. Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.
Recasens-Zorzo C; Cardesa-Salzmann T; Petazzi P; Ros-Blanco L; Esteve-Arenys A; Clot G; Guerrero-Hernández M; Rodríguez V; Soldini D; Valera A; Moros A; Climent F; González-Barca E; Mercadal S; Arenillas L; Calvo X; Mate JL; Gutiérrez-García G; Casanova I; Mangues R; Sanjuan-Pla A; Bueno C; Menéndez P; Martínez A; Colomer D; Tejedor RE; Teixidó J; Campo E; López-Guillermo A; Borrell JI; Colomo L; Pérez-Galán P; Roué G
Haematologica; 2019 Apr; 104(4):778-788. PubMed ID: 29954928
[TBL] [Abstract][Full Text] [Related]
2. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
[TBL] [Abstract][Full Text] [Related]
3. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
[TBL] [Abstract][Full Text] [Related]
4. Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells.
Delgado-Martín C; Escribano C; Pablos JL; Riol-Blanco L; Rodríguez-Fernández JL
J Biol Chem; 2011 Oct; 286(43):37222-36. PubMed ID: 21878648
[TBL] [Abstract][Full Text] [Related]
5. The
Pansy K; Feichtinger J; Ehall B; Uhl B; Sedej M; Roula D; Pursche B; Wolf A; Zoidl M; Steinbauer E; Gruber V; Greinix HT; Prochazka KT; Thallinger GG; Heinemann A; Beham-Schmid C; Neumeister P; Wrodnigg TM; Fechter K; Deutsch AJ
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554271
[TBL] [Abstract][Full Text] [Related]
6. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
7. Angiogenic effects of stromal cell-derived factor-1 (SDF-1/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR4 in human critical leg ischemia.
Ho TK; Tsui J; Xu S; Leoni P; Abraham DJ; Baker DM
J Vasc Surg; 2010 Mar; 51(3):689-99. PubMed ID: 20206813
[TBL] [Abstract][Full Text] [Related]
8. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
Wong C; Laddha SV; Tang L; Vosburgh E; Levine AJ; Normant E; Sandy P; Harris CR; Chan CS; Xu EY
Cell Death Dis; 2014 Oct; 5(10):e1450. PubMed ID: 25299775
[TBL] [Abstract][Full Text] [Related]
9. Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis.
Badr G; Lefevre EA; Mohany M
PLoS One; 2011; 6(9):e23741. PubMed ID: 21912642
[TBL] [Abstract][Full Text] [Related]
10. Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways.
Shen X; Artinyan A; Jackson D; Thomas RM; Lowy AM; Kim J
Pancreas; 2010 Jan; 39(1):81-7. PubMed ID: 19820417
[TBL] [Abstract][Full Text] [Related]
11. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
12. C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges.
Du H; Gao L; Luan J; Zhang H; Xiao T
Acta Haematol; 2019; 142(2):64-70. PubMed ID: 31096215
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator‑activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis.
Qin L; Gong C; Chen AM; Guo FJ; Xu F; Ren Y; Liao H
Mol Med Rep; 2014 Aug; 10(2):695-700. PubMed ID: 24842333
[TBL] [Abstract][Full Text] [Related]
14. Roles of SDF-1/CXCR4 axis in cartilage endplate stem cells mediated promotion of nucleus pulposus cells proliferation.
He Z; Jia M; Yu Y; Yuan C; Wang J
Biochem Biophys Res Commun; 2018 Nov; 506(1):94-101. PubMed ID: 30340825
[TBL] [Abstract][Full Text] [Related]
15. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4.
Yi L; Zhou X; Li T; Liu P; Hai L; Tong L; Ma H; Tao Z; Xie Y; Zhang C; Yu S; Yang X
J Exp Clin Cancer Res; 2019 Aug; 38(1):339. PubMed ID: 31382985
[TBL] [Abstract][Full Text] [Related]
16. CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.
Moreno MJ; Gallardo A; Novelli S; Mozos A; Aragó M; Pavón MÁ; Céspedes MV; Pallarès V; Falgàs A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I
PLoS One; 2018; 13(6):e0198789. PubMed ID: 29920526
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
Peng SB; Zhang X; Paul D; Kays LM; Ye M; Vaillancourt P; Dowless M; Stancato LF; Stewart J; Uhlik MT; Long H; Chu S; Obungu VH
PLoS One; 2016; 11(3):e0150585. PubMed ID: 26954567
[TBL] [Abstract][Full Text] [Related]
19. MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis.
Alampour-Rajabi S; El Bounkari O; Rot A; Müller-Newen G; Bachelerie F; Gawaz M; Weber C; Schober A; Bernhagen J
FASEB J; 2015 Nov; 29(11):4497-511. PubMed ID: 26139098
[TBL] [Abstract][Full Text] [Related]
20. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways.
Vlahakis SR; Villasis-Keever A; Gomez T; Vanegas M; Vlahakis N; Paya CV
J Immunol; 2002 Nov; 169(10):5546-54. PubMed ID: 12421931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
